Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

NCT06162377 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Methylnaltrexone

Sponsor

M.D. Anderson Cancer Center